

美時公告 6 月自結合併營收大躍進、單月營收一舉突破新台幣 10 億大關

累計第 2 季自結合併營收逾台幣 27 億元，較去年同期大幅成長 43%、創歷史次高

Lotus Reported Unaudited June Revenues of NT\$1,052 Million, a 48% Increase YoY

Outstanding performance from both Export Business and Asian Business concluded its Q2'20 with second record high quarterly sales of more than NT\$2.7 billion, another 43% growth YoY

2020 年 7 月 10 日，台北

July 10th, 2020, Taipei

特殊學名藥廠美時化學製藥（以下簡稱“美時”，台灣證券交易所股票代碼：1795）公佈 2020 年 6 月自結合併營收達新台幣 1,052,244 仟元，較去年同期成長逾 48%，不僅再創今年新高，這也是連續第 4 個月營收呈現強勁的月增/年增成長。

美時表示本月外銷業務與亞太區域業務皆有重要進展、表現亮眼 – 不僅重磅產品維持領先成長，新市場的拓展策略亦開始發酵、注入營收貢獻；其中，戒癮用藥 Buprenorphine/Naloxone 舌下含片客戶在美國市佔的穩定領先持續地強化外銷業務的成長動能。而在亞太區域市場方面，韓國市場減重產品 Qsymia 在 5 月份更進一步地在當地前五大減重產品、包含傳統用藥及新一代處方、取得領先地位，帶動後續營收表現；此外，除了整併東南亞市場的營收貢獻外，美時本月在大陸市場部分授權品項的進度亦有所斬獲、故有權利金收入之認列，亦為亞太區域市場成長動能再添新血。

Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that its consolidated sales for June 2020 was NT\$1,052,244 thousand, representing a 48% increase over the same period last year. This is also the fourth month in a row delivering robust MoM/YoY sales growth YTD'20.

Both Export Business and Asian Business performed well with significant progress – not only flagship products continued to grow but also contribution from new market expansion started to kick in. The stable leading market share in the US of Buprenorphine/Naloxone film kept driving the growth momentum of its Export Business. As for Asian Business, Qsymia in May has further taken the leading position among Top 5 anti-obesity products, including legacy and 2nd generation ones, in Korea which then turned into solid number in June. Moreover, in addition to SEA markets, the Company also achieved several milestones for licensing projects in China and thus recognized some milestone revenues accordingly.

第二季自結合併營收亦表現亮眼，達新台幣 2,702,864 仟元，較去年同期大幅成長 43%、亦較前一季增加約 38%。而今年上半年各區域市場成功打下的成長動能皆將成為未來持續拓展、強化獲利的堅強基石。

Lotus also reported a second historical high quarterly sales of NT\$2,702,864 thousand for Q2'20, a

43% growth compared to the same period last year and a 38% increase over Q1'20. All the growth drivers set in the first half of 2020 will become solid fundamentals for further developments.

新聞聯繫人Contact:

美時製藥 投資人關係處長 樂君儀 (02)2700 5908 investor@lotuspharm.com

Angela Luan, Investor Relations Director

關於美時：

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，為一以台灣為基地供應全球市場之學名藥廠，高價值產品線涵蓋中樞神經系統、心血管疾病、癌症、女性保健、減肥等，並以錠劑、膠囊及軟膠囊劑型為主；美時自 2014 年成為艾威群集團的一員，現專注於快速成長的抗癌市場，並矢志透過整合台灣與韓國首屈一指的研發平台與其製造優勢嘉惠病患、員工與股東。美時的行銷與業務通路包含直營的亞洲市場及艾威群集團橫跨全球超過 30 個國家的商業網絡，此外，美時亦積極與一線藥廠就產品線策略結盟，是少數能進軍所有市場的新興藥廠。

About Lotus

Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.

聲明：

本文件及同時發佈之相關資訊內含有預測性敘述。除針對已發生事實，所有對美時製藥(以下簡稱本公司)未來經營業務、可能發生之事件及展望（包括但不限於預測、目標、估算和營運計劃）之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性的影響，造成與實際情況有相當差異，這些因素包括但不限於價格波動、實際需求、匯率變動、市占率、市場競爭情況，法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等，及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估，本公司不負日後更新之責。